OptimizeRx (OPRX) Stock Forecast, Price Target & Predictions

OverviewRevenue Ownership Financials Chart Transcripts

OPRX Stock Forecast

OptimizeRx stock forecast is as follows: an average price target of $15.00 (represents a 257.14% upside from OPRX’s last price of $4.20) and a rating consensus of 'Buy', based on 3 wall street analysts offering a 1-year stock forecast.

OPRX Price Target

The average price target for OptimizeRx (OPRX) is $15.00 based on 1-year price targets from 3 Wall Street analysts in the past 3 months, with a price target range of $15.00 to $15.00. This represents a potential 257.14% upside from OPRX's last price of $4.20.

OPRX Analyst Ratings

Buy

According to 3 Wall Street analysts, OptimizeRx's rating consensus is 'Buy'. The analyst rating breakdown for OPRX stock is 0 'Strong Buy' (0.00%), 3 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

OptimizeRx Price Target by Analyst

Date	Analyst	Company	Price Target	Price when Published	Price Target/Price when Published	Price Target/Last Closing Price
Apr 04, 2024	Constantine Davides	JMP Securities	$15.00	$11.17	34.29%	257.14%

Row per page

Go to

The latest OptimizeRx stock forecast, released on Apr 04, 2024 by Constantine Davides from JMP Securities, set a price target of $15.00, which represents a 34.29% increase from the stock price at the time of the forecast ($11.17), and a 257.14% increase from OPRX last price ($4.20).

OptimizeRx Price Target by Period

	1M	3M	12M
# Anlaysts	-	-	1
Avg Price Target	-	-	$15.00
Last Closing Price	$4.20	$4.20	$4.20
Upside/Downside	-100.00%	-100.00%	257.14%

In the current month, the average price target of OptimizeRx stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to OptimizeRx's last price of $4.20. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades

Date	Company	Previous Rating	New Rating	Rating Change
Aug 12, 2024	JMP Securities	Market Outperform	Market Outperform	Hold
Jun 21, 2024	Stifel Nicolaus	Market Outperform	Market Outperform	Hold
May 15, 2024	RBC Capital	Underperform	Underperform	Hold
May 15, 2024	Stifel Nicolaus	Market Outperform	Market Outperform	Hold
May 15, 2024	JMP Securities	Outperform	Outperform	Hold
Apr 04, 2024	JMP Securities	Market Outperform	Outperform	Initialise
Apr 04, 2024	JMP Securities	-	Market Outperform	Initialise
Apr 01, 2024	RBC Capital	Buy	Buy	Hold
Aug 10, 2022	RBC Capital	Outperform	Outperform	Hold
Jul 15, 2022	SVB Leerink	-	Buy	Initialise

Row per page

Go to

OptimizeRx's last stock rating was published by JMP Securities on Aug 12, 2024. The company gave OPRX a "Market Outperform" rating, the same as its previous rate.

OptimizeRx Financial Forecast

OptimizeRx Revenue Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Mar 18	Dec 17
Revenue	-	-	-	-	-	-	-	-	-	$16.33M	$13.82M	$13.00M	$19.65M	$15.09M	$13.98M	$13.73M	$20.31M	$16.12M	$13.63M	$11.23M	$16.43M	$10.52M	$8.78M	$7.58M	$7.38M	$5.00M	$7.01M	$5.21M	$4.11M	$4.01M
Avg Forecast	$32.91M	$24.70M	$22.18M	$21.00M	$29.54M	$24.99M	$20.16M	$18.13M	$27.92M	$15.14M	$14.80M	$12.35M	$21.77M	$14.92M	$17.06M	$13.55M	$20.16M	$15.14M	$12.45M	$10.47M	$16.01M	$9.77M	$7.97M	$7.03M	$7.57M	$7.18M	$6.69M	$5.10M	$8.22M	$4.01M
High Forecast	$33.76M	$25.34M	$22.76M	$21.38M	$30.26M	$25.05M	$20.16M	$18.13M	$28.16M	$15.20M	$15.19M	$12.68M	$22.33M	$14.92M	$17.06M	$13.55M	$20.16M	$15.14M	$12.45M	$10.47M	$16.01M	$9.77M	$7.97M	$7.03M	$7.57M	$7.18M	$6.69M	$5.10M	$9.86M	$4.81M
Low Forecast	$31.88M	$23.93M	$21.49M	$20.63M	$28.42M	$24.93M	$20.16M	$18.13M	$27.66M	$15.08M	$14.34M	$11.97M	$21.09M	$14.92M	$17.06M	$13.55M	$20.16M	$15.14M	$12.45M	$10.47M	$16.01M	$9.77M	$7.97M	$7.03M	$7.57M	$7.18M	$6.69M	$5.10M	$6.58M	$3.21M
# Analysts	1	1	1	3	5	4	1	1	3	1	1	1	1	1	1	1	1	1	1	1	9	8	7	6	5	5	5	5	13	11
Surprise %	-	-	-	-	-	-	-	-	-	1.08%	0.93%	1.05%	0.90%	1.01%	0.82%	1.01%	1.01%	1.07%	1.09%	1.07%	1.03%	1.08%	1.10%	1.08%	0.98%	0.70%	1.05%	1.02%	0.50%	1.00%

OptimizeRx's average Quarter revenue forecast for Dec 23 based on 3 analysts is $27.92M, with a low forecast of $27.66M, and a high forecast of $28.16M. OPRX's average Quarter revenue forecast represents a 70.94% increase compared to the company's last Quarter revenue of $16.33M (Sep 23).

OptimizeRx EBITDA Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Mar 18	Dec 17
# Analysts	1	1	1	3	5	4	1	1	3	1	1	1	1	1	1	1	1	1	1	1	9	8	7	6	5	5	5	5	13	11
EBITDA	-	-	-	-	-	-	-	-	-	$-3.09M	$-4.42M	$-6.60M	$-407.80K	$-3.24M	$-3.33M	$-3.29M	$1.01M	$565.93K	$880.06K	$-111.20K	$1.76M	$240.53K	$-556.67K	$-1.68M	$-2.45M	$-1.25M	$642.19K	$196.83K	$-134.71K	$-261.93K
Avg Forecast	$-3.45M	$-2.59M	$-2.33M	$-2.20M	$-3.10M	$-2.62M	$-2.11M	$-5.26M	$-2.93M	$-1.59M	$-1.55M	$-4.16M	$1.06M	$-1.10M	$-1.26M	$-3.29M	$-1.49M	$-1.12M	$-917.80K	$-111.20K	$-1.18M	$-720.25K	$-587.88K	$-1.85M	$-557.81K	$-529.57K	$-493.16K	$620.01K	$-181.85K	$-261.93K
High Forecast	$-3.34M	$-2.51M	$-2.25M	$-2.16M	$-2.98M	$-2.61M	$-2.11M	$-4.21M	$-2.90M	$-1.58M	$-1.50M	$-3.33M	$1.27M	$-1.10M	$-1.26M	$-2.63M	$-1.49M	$-1.12M	$-917.80K	$-88.96K	$-1.18M	$-720.25K	$-587.88K	$-1.48M	$-557.81K	$-529.57K	$-493.16K	$744.02K	$-145.48K	$-209.54K
Low Forecast	$-3.54M	$-2.66M	$-2.39M	$-2.24M	$-3.17M	$-2.63M	$-2.11M	$-6.32M	$-2.95M	$-1.59M	$-1.59M	$-4.99M	$845.31K	$-1.10M	$-1.26M	$-3.95M	$-1.49M	$-1.12M	$-917.80K	$-133.44K	$-1.18M	$-720.25K	$-587.88K	$-2.22M	$-557.81K	$-529.57K	$-493.16K	$496.01K	$-218.22K	$-314.31K
Surprise %	-	-	-	-	-	-	-	-	-	1.94%	2.85%	1.59%	-0.39%	2.95%	2.65%	1.00%	-0.68%	-0.51%	-0.96%	1.00%	-1.50%	-0.33%	0.95%	0.91%	4.40%	2.36%	-1.30%	0.32%	0.74%	1.00%

1 analysts predict OPRX's average Quarter EBITDA for Mar 22 to be $-3.29M, with a high of $-2.63M and a low of $-3.95M. This is -426.15% lower than OptimizeRx's previous annual EBITDA (Dec 21) of $1.01M.

OptimizeRx Net Income Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Mar 18	Dec 17
# Analysts	1	1	1	3	5	4	1	1	3	1	1	1	1	1	1	1	1	1	1	1	9	8	7	6	5	5	5	5	13	11
Net Income	-	-	-	-	-	-	-	-	-	$-2.87M	$-4.16M	$659.07M	$212.68K	$-3.18M	$-3.86M	$-3.76M	$623.46K	$39.89K	$352.10K	$-637.38K	$1.36M	$-282.89K	$-1.08M	$-2.20M	$-1.98M	$-1.57M	$406.62K	$6.53K	$-189.18K	$-237.06K
Avg Forecast	$5.46M	$1.37M	$-88.52K	$-331.85K	$4.56M	$1.08M	$-1.17M	$-6.02M	$7.00M	$456.27K	$-391.10K	$-4.76M	$653.15K	$616.20K	$1.64M	$-3.76M	$3.76M	$2.37M	$1.31M	$-637.38K	$2.83M	$730.32K	$-547.74K	$-2.42M	$91.29K	$1.41M	$1.41M	$20.57K	$-255.39K	$-237.06K
High Forecast	$5.65M	$1.42M	$-84.94K	$-318.45K	$4.91M	$1.10M	$-1.13M	$-4.81M	$8.35M	$471.64K	$-375.30K	$-3.81M	$783.78K	$616.20K	$1.64M	$-3.01M	$3.76M	$2.37M	$1.31M	$-509.90K	$2.83M	$730.32K	$-547.74K	$-1.94M	$91.29K	$1.41M	$1.41M	$24.68K	$-204.31K	$-189.65K
Low Forecast	$5.24M	$1.32M	$-91.50K	$-343.03K	$4.33M	$1.05M	$-1.21M	$-7.22M	$5.12M	$437.84K	$-404.27K	$-5.71M	$522.52K	$616.20K	$1.64M	$-4.51M	$3.76M	$2.37M	$1.31M	$-764.85K	$2.83M	$730.32K	$-547.74K	$-2.91M	$91.29K	$1.41M	$1.41M	$16.45K	$-306.47K	$-284.47K
Surprise %	-	-	-	-	-	-	-	-	-	-6.28%	10.64%	-138.53%	0.33%	-5.16%	-2.35%	1.00%	0.17%	0.02%	0.27%	1.00%	0.48%	-0.39%	1.97%	0.91%	-21.74%	-1.11%	0.29%	0.32%	0.74%	1.00%

OptimizeRx's average Quarter net income forecast for Jun 23 is $-391.10K, with a range of $-404.27K to $-375.30K. OPRX's average Quarter net income forecast represents a -100.06% decrease compared to the company's last Quarter net income of $659.07M (Mar 23).

OptimizeRx SG&A Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Mar 18	Dec 17
# Analysts	1	1	1	3	5	4	1	1	3	1	1	1	1	1	1	1	1	1	1	1	9	8	7	6	5	5	5	5	13	11
SG&A	-	-	-	-	-	-	-	-	-	$12.89M	$12.24M	$14.03M	$14.26M	$12.14M	$11.88M	$11.86M	$12.26M	$8.08M	$6.93M	$5.92M	$7.18M	$4.88M	$4.86M	$5.32M	$4.47M	$3.28M	$3.33M	$3.09M	$2.03M	$2.15M
Avg Forecast	$22.54M	$16.92M	$15.19M	$14.38M	$20.23M	$17.12M	$13.81M	$17.55M	$19.12M	$10.37M	$10.14M	$8.46M	$12.84M	$10.22M	$11.69M	$10.97M	$13.81M	$10.37M	$8.53M	$5.92M	$10.96M	$6.69M	$5.46M	$5.85M	$5.18M	$4.92M	$4.58M	$3.49M	$2.74M	$2.15M
High Forecast	$23.12M	$17.36M	$15.59M	$14.64M	$20.73M	$17.16M	$13.81M	$21.06M	$19.29M	$10.41M	$10.40M	$8.68M	$15.41M	$10.22M	$11.69M	$13.16M	$13.81M	$10.37M	$8.53M	$7.10M	$10.96M	$6.69M	$5.46M	$7.02M	$5.18M	$4.92M	$4.58M	$3.49M	$3.28M	$2.58M
Low Forecast	$21.84M	$16.39M	$14.72M	$14.13M	$19.46M	$17.08M	$13.81M	$14.04M	$18.95M	$10.33M	$9.82M	$8.20M	$10.27M	$10.22M	$11.69M	$8.77M	$13.81M	$10.37M	$8.53M	$4.73M	$10.96M	$6.69M	$5.46M	$4.68M	$5.18M	$4.92M	$4.58M	$3.49M	$2.19M	$1.72M
Surprise %	-	-	-	-	-	-	-	-	-	1.24%	1.21%	1.66%	1.11%	1.19%	1.02%	1.08%	0.89%	0.78%	0.81%	1.00%	0.65%	0.73%	0.89%	0.91%	0.86%	0.67%	0.73%	0.88%	0.74%	1.00%

OptimizeRx's average Quarter SG&A projection for Dec 23 is $19.12M, based on 3 Wall Street analysts, with a range of $18.95M to $19.29M. The forecast indicates a 48.38% rise compared to OPRX last annual SG&A of $12.89M (Sep 23).

OptimizeRx EPS Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Mar 18	Dec 17
# Analysts	1	1	1	3	5	4	1	1	3	1	1	1	1	1	1	1	1	1	1	1	9	8	7	6	5	5	5	5	13	11
EPS	-	-	-	-	-	-	-	-	-	$-0.17	$-0.24	$38.55	$0.01	$-0.18	$-0.21	$-0.21	$0.04	-	$0.02	$-0.04	$0.09	$-0.02	$-0.07	$-0.15	$-0.14	$-0.11	$0.03	-	$-0.02	$-0.03
Avg Forecast	$0.30	$0.08	$-0.00	$-0.02	$0.25	$0.06	$-0.06	$-0.13	$0.38	$0.03	$-0.02	$-0.08	$0.24	$0.03	$0.09	$-0.01	$0.21	$0.13	$0.07	$0.01	$0.15	$0.04	$-0.03	$-0.04	$0.01	$0.08	$0.08	$0.02	$-0.08	$-0.03
High Forecast	$0.31	$0.08	$-0.00	$-0.02	$0.27	$0.06	$-0.06	$-0.12	$0.46	$0.03	$-0.02	$-0.08	$0.25	$0.03	$0.09	$-0.01	$0.21	$0.13	$0.07	$0.01	$0.15	$0.04	$-0.03	$-0.04	$0.01	$0.08	$0.08	$0.02	$-0.06	$-0.02
Low Forecast	$0.29	$0.07	$-0.01	$-0.02	$0.24	$0.06	$-0.07	$-0.13	$0.28	$0.02	$-0.02	$-0.08	$0.23	$0.03	$0.09	$-0.01	$0.21	$0.13	$0.07	$0.01	$0.15	$0.04	$-0.03	$-0.04	$0.01	$0.08	$0.08	$0.02	$-0.10	$-0.04
Surprise %	-	-	-	-	-	-	-	-	-	-6.80%	11.20%	-481.87%	0.05%	-5.33%	-2.33%	17.50%	0.17%	0.02%	0.28%	-5.00%	0.58%	-0.50%	2.33%	3.75%	-28.00%	-1.42%	0.39%	0.02%	0.24%	1.00%

According to 1 Wall Street analysts, OptimizeRx's projected average Quarter EPS for Jun 23 is $-0.02, with a low estimate of $-0.02 and a high estimate of $-0.02. This represents a -100.06% decrease compared to OPRX previous annual EPS of $38.55 (Mar 23).

OptimizeRx Peer Comparison by Price Target

Ticker	Company	Last Closing Price	Avg Price Target	Upside/Downside	Avg Rating
ACCD	Accolade	$3.38	$14.81	338.17%	Buy
OPRX	OptimizeRx	$4.20	$15.00	257.14%	Buy
DH	Definitive Healthcare	$4.12	$9.50	130.58%	Hold
FORA	Forian	$2.03	$4.50	121.67%	Buy
CERT	Certara	$9.99	$19.33	93.49%	Buy
PRVA	Privia Health Group	$20.95	$33.82	61.43%	Buy
HQY	HealthEquity	$102.40	$97.00	-5.27%	Buy
DOCS	Doximity	$52.21	$49.10	-5.96%	Buy
HSTM	HealthStream	$31.31	$29.00	-7.38%	Buy

OPRX Forecast FAQ

Is OptimizeRx a good buy?

Yes, according to 3 Wall Street analysts, OptimizeRx (OPRX) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 3 'Buy' recommendations, accounting for 100.00% of OPRX's total ratings.

What is OPRX's price target?

OptimizeRx (OPRX) average price target is $15 with a range of $15 to $15, implying a 257.14% from its last price of $4.2. The data is based on 3 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will OptimizeRx stock go up soon?

According to Wall Street analysts' prediction for OPRX stock, the company can go up by 257.14% (from the last price of $4.2 to the average price target of $15), up by 257.14% based on the highest stock price target, and up by 257.14% based on the lowest stock price target.

Can OptimizeRx stock reach $6?

OPRX's average twelve months analyst stock price target of $15 supports the claim that OptimizeRx can reach $6 in the near future.

What are OptimizeRx's analysts' financial forecasts?

OptimizeRx's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $92.83M (high $93.61M, low $91.65M), average EBITDA is $-13.096M (high $-11.919M, low $-14.23M), average net income is $-1.554M (high $75.59K, low $-3.059M), average SG&A $68.71M (high $72.75M, low $64.39M), and average EPS is $0.117 (high $0.146, low $0.0962). OPRX's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $100.79M (high $103.23M, low $97.94M), average EBITDA is $-10.568M (high $-10.268M, low $-10.824M), average net income is $6.42M (high $6.66M, low $6.13M), average SG&A $69.04M (high $70.71M, low $67.08M), and average EPS is $0.352 (high $0.365, low $0.336).

Did the OPRX's actual financial results beat the analysts' financial forecasts?

Based on OptimizeRx's last annual report (Dec 2022), the company's revenue was $62.45M, which missed the average analysts forecast of $67.3M by -7.20%. Apple's EBITDA was $-10.269M, beating the average prediction of $-4.591M by 123.69%. The company's net income was $-10.586M, beating the average estimation of $-849K by 1147.58%. Apple's SG&A was $49.24M, beating the average forecast of $45.71M by 7.70%. Lastly, the company's EPS was $-0.6, missing the average prediction of $0.353 by -269.89%. In terms of the last quarterly report (Sep 2023), OptimizeRx's revenue was $16.33M, beating the average analysts' forecast of $15.14M by 7.87%. The company's EBITDA was $-3.087M, beating the average prediction of $-1.587M by 94.45%. OptimizeRx's net income was $-2.865M, missing the average estimation of $456.27K by -727.98%. The company's SG&A was $12.89M, beating the average forecast of $10.37M by 24.27%. Lastly, the company's EPS was $-0.17, missing the average prediction of $0.025 by -780.00%